Axatilimab, Anti-CSF1R, a New Treatment Class

Opinion
Video

Corey Cutler, MD, MPH, discusses how axatilimab’s mechanism of action differs from currently available therapies for patients with chronic GVHD.

Video content above is prompted by the following questions:

  • As a first in class anti-CSF-1R antibody, please discuss how axatilimab's novel mechanism of action differs from current chronic GVHD (cGVHD) therapies?
    • How significant is it to target the CSF-1/ CSF-1R pathway in cGVHD pathogenesis?
Related Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Hannah Choe, MD, an expert on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content